Novartis to acquire PI3K-alpha inhibitor program from Synnovation in deal worth up to USD3bn

Humacyte prices USD20m registered direct offering

Curia expands Glasgow manufacturing capacity and enhances CLD platform

Congruence Therapeutics secures USD39.5m financing

Pfizer reports Phase 3 TALAPRO-3 results showing improved outcomes in metastatic prostate cancer

Specific Biologics and Western University win grant to develop ML platform to accelerate development of Dualase-based therapeutics 

Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform

IsomAb names new CEO

Mirecule expands collaboration with Sanofi to advance FSHD therapy

Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease

Alebund Pharmaceuticals signs licensing and equity agreements with R1 Therapeutics

Apertura Gene Therapy agrees manufacturing collaboration with Viralgen

Humacyte submits Israel MAA for Symvess arterial trauma repair

Sentynl Therapeutics and PRG S&T enter licensing agreement for potential HGPS treatment

ONL Therapeutics reports start of European Phase 2 trial of xelafaslatide for GA associated with dry AMD